Myocardial cell death is initiated by excessive mitochondrial Ca 21 entry causing Ca 21 overload, mitochondrial permeability transition pore (mPTP) opening and dissipation of the mitochondrial inner membrane potential (DYm) 1,2 . However, the signalling pathways that control mitochondrial Ca 21 entry through the inner membrane mitochondrial Ca 21 uniporter (MCU) [3] [4] [5] are not known. The multifunctional Ca 21 /calmodulin-dependent protein kinase II (CaMKII) is activated in ischaemia reperfusion, myocardial infarction and neurohumoral injury, common causes of myocardial death and heart failure; these findings suggest that CaMKII could couple disease stress to mitochondrial injury. Here we show that CaMKII promotes mPTP opening and myocardial death by increasing MCU current (I MCU ). Mitochondrial-targeted CaMKII inhibitory protein or cyclosporin A, an mPTP antagonist with clinical efficacy in ischaemia reperfusion injury 6 , equivalently prevent mPTP opening, DYm deterioration and diminish mitochondrial disruption and programmed cell death in response to ischaemia reperfusion injury. Mice with myocardial and mitochondrial-targeted CaMKII inhibition have reduced I MCU and are resistant to ischaemia reperfusion injury, myocardial infarction and neurohumoral injury, suggesting that pathological actions of CaMKII are substantially mediated by increasing I MCU . Our findings identify CaMKII activity as a central mechanism for mitochondrial Ca 21 entry in myocardial cell death, and indicate that mitochondrial-targeted CaMKII inhibition could prevent or reduce myocardial death and heart failure in response to common experimental forms of pathophysiological stress.
Excessive activation of the multifunctional CaMKII by Ca 21 triggers myocardial death and heart failure 7, 8 . Excessive CaMKII activity promotes multiple defects in myocardial Ca 21 homeostasis including increased mitochondrial Ca 21 (refs 9, 10) . CaMKII inhibition is protective against ischaemia reperfusion, myocardial infarction and neurohumoral toxicity, clinically relevant forms of myocardial injury marked by disturbed intracellular Ca 21 homeostasis 7, 8, 11 , but the mechanisms for myocardial protection by CaMKII inhibition are unknown. Excessive increases in mitochondrial Ca 21 lead to mPTP opening and dissipation of the DYm (refs 1, 2). We first asked if excessive activation of CaMKII localized in mitochondria could be a mechanism for myocardial dysfunction or death during ischaemia reperfusion injury, because ischaemia reperfusion injury occurs in the setting of increased mitochondrial Ca 21 and ischaemia reperfusion injury is alleviated in rats by Ru360 (ref. 12), a selective inhibitor of I MCU (ref. 12) , and in patients by cyclosporin A (CsA), an inhibitor of mPTP 6 . Here we show that mitochondrial-targeted CaMKII inhibition or treatment with CsA, an mPTP antagonist with clinical efficacy in ischaemia reperfusion injury 6 , are both protective against mPTP opening, loss of DYm, mitochondrial disruption and programmed cell death in response to ischaemia reperfusion, myocardial infarction or isoprenaline. The myocardial protective effects of mitochondrial CaMKII inhibition are multivalent and involve increasing mPTP Ca 21 tolerance and reduction in I MCU .
To test if CaMKII catalytic activity is the mechanism for Ca 21 to affect downstream responses to ischaemia reperfusion injury, we developed mice with myocardial-delimited CaMKII inhibition by transgenic expression of CaMKIIN, the most potent and specific CaMKII inhibitory protein 13 . We engineered CaMKIIN with a palmitoylation sequence to enhance partitioning into intracellular membranes. We identified CaMKIIN expression in isolated mitochondria of transgenic mice ( Supplementary Fig. 1a, b ). To determine if CaMKIIN transgenic mice were resistant to ischaemia reperfusion injury by a Ca 21 -regulated pathway, we used isolated, perfused, working mouse hearts to measure directly myocardial mechanical responses to ischaemia reperfusion injury under conditions designed to restrict glycolytic metabolism. Wild-type hearts or hearts with transgenic CaMKIIN expression were perfused with a pyruvate-containing solution (at non-physiological levels) without glucose (so that ATP production relied on oxidative metabolism), and CsA (to prevent mPTP opening), or vehicle (Supplementary Fig. 2a -c). Left ventricular developed pressure (LVDP) ( Supplementary Fig. 2b ) and the first derivative of left ventricular developed pressure ( Supplementary Fig. 3a ) were reduced in wild-type vehicle-treated hearts after ischaemia reperfusion injury, but were preserved at normal levels after ischaemia reperfusion injury in hearts with CaMKII inhibition or in wild-type hearts treated with CsA. Baseline recordings were similar between CaMKIIN-expressing, wild type and wild type with CsA ( Supplementary Fig. 3b ). The area of infarcted myocardium after ischaemia reperfusion injury (Supplementary Fig. 2d , e) was 66 6 3.3% of the area at risk for wild-type littermate control hearts, and was reduced by half with CsA or CaMKIIN expression. The relative area of infarcted myocardium ( Supplementary Fig. 2e ) was inversely related to the extent of mechanical recovery ( Supplementary Fig. 2c ), suggesting that the beneficial effects of CsA and CaMKII inhibition ultimately derived from prevention of myocardial death in response to ischaemia reperfusion injury. We measured caspase 9 activity, a marker of mitochondrial-triggered apoptosis 14 . Caspase 9 was significantly reduced in the CaMKIIN transgenic hearts after ischaemia reperfusion injury and in wild-type hearts treated with CsA ( Supplementary Fig. 2f ).
We tested if transgenic expression of CaMKIIN protected mitochondria from ischaemia reperfusion injury. Mitochondria are structurally dynamic organelles and loss of the highly ordered internal membrane cristae is an ultrastructural correlate of mPTP opening, loss of DYm and apoptosis initiation 15 . We used transmission electron microscopy (TEM) to examine mitochondrial ultrastructure and to quantify mitochondrial disruption ( Supplementary Fig. 2g , h) after ischaemia reperfusion injury. Mitochondria suffered extensive disruption after ischaemia reperfusion injury in vehicle-treated wild-type hearts; however, mitochondria were significantly protected in CsAtreated wild-type hearts. In contrast, mitochondria from CaMKIIN transgenic hearts were resistant to ischaemia reperfusion injury, with or without CsA treatment ( Supplementary Fig. 2h ). These data show that infarct size, mitochondrial structural integrity and mitochondrialtriggered cell death and dysfunction are similarly improved by CsA or CaMKII inhibition, consistent with a model in which CsA and CaMKII both engage a mitochondrial pathway leading to mPTP opening during pathological stress.
To better elucidate the protective effects of mitochondrial CaMKIIN expression, we measured Ca 21 -induced injury in isolated mitochondria. Loss of mitochondria function by mPTP opening can be measured in isolated mitochondria in response to supraphysiological mitochondrial Ca 21 increases 16 . Decreases in light scattering are a correlate of mPTP opening 17 . We found that mitochondria with CaMKIIN expression were resistant to Ca 21 -triggered decreases in light scattering compared to wild-type controls ( Fig. 1a ). We corroborated this finding using another mitochondrial integrity assay in which a fluorescence decrease corresponds to a loss of DYm. We loaded mitochondria isolated from wild-type and CaMKIIN transgenic mice with a voltagesensitive fluorescent indicator, JC-1 (ref. 15) , to compare their DYm responses to Ca 21 . Mitochondria isolated from wild-type hearts were significantly more sensitive to DYm loss in response to a lethal Ca 21 challenge compared to mitochondria with CaMKIIN expression ( Fig. 1b ). Treatment with CsA, an mPTP opening inhibitor, preserved the DYm during exogenous Ca 21 challenge in mitochondria isolated from wild-type hearts, whereas mitochondria derived from CaMKIIN transgenic hearts were protected without requiring CsA treatment ( Fig. 1c ).
We detected CaMKII associated with mitochondria and mitoplasts, inner mitochondrial membrane vesicles from osmotically shocked isolated cardiac mitochondria ( Supplementary Fig. 4a-d ), similar to previous studies 18, 19 . However, CaMKII may contribute to Ca 21 overload and myocardial death by actions at extra-mitochondrial Ca 21 homeostatic proteins 20 . Therefore, we developed transgenic mice with CaMKIIN expression limited to myocardial mitochondria (mtCaMKIIN) to test if CaMKII inhibition targeted to mitochondria affected mitochondria susceptibility to excess Ca 21 . Unlike CaMKIIN transgenic mice, hearts expressing mtCaMKIIN have expression restricted to mitoplasts ( Supplementary Fig. 1b ). Mitochondria isolated from mtCaMKIIN hearts showed no difference in baseline metabolic function compared with wild-type littermates ( Supplementary  Fig. 5 ). We measured mitochondrial Ca 21 uptake with a membraneimpermeable indicator, Calcium green-5N (ref. 4) . We found that cardiomyocytes from mtCaMKIIN transgenic mice had significantly slower mitochondrial Ca 21 uptake (measured as a rate of decrease in Calcium green-5N fluorescence), than mitochondria of wild-type cardiomyocytes ( Fig. 1d , e). We tested the overall Ca 21 capacity of myocardial mitochondria with serial additions of Ca 21 , and found that mtCaMKIIN expression increased the mitochondrial Ca 21 capacity reached before mPTP opening ( Supplementary Fig. 6a, b ). We monitored mitochondrial Ca 21 concentration changes within the mitochondria using Cameleon, a mitochondrial-targeted GFP-based Ca 21 indicator 21 . HeLa cells co-transfected with Cameleon and mtCaMKIIN show reduced ATP-triggered Ca 21 entry into mitochondria compared with control cells without mtCaMKIIN expression ( Fig. 1f and Supplementary Fig. 7a, b ). These data indicate that the protective benefits of CaMKII inhibition against mitochondrial stress derive from reducing mitochondria Ca 21 entry and enhancing mPTP Ca 21 tolerance.
The MCU is a major Ca 21 entry pathway through the mitochondrial inner membrane [3] [4] [5] . In the presence of I MCU inhibitor drugs, isolated cardiomyocytes 22 and perfused hearts 12 are resistant to opening and cell death after Ca 21 challenge. To examine potential effects of CaMKII on the MCU, we performed mitoplast patch clamp studies.
We used Ru360, a specific mitochondrial calcium uptake inhibitor, and we measured an Ru360-sensitive mitochondrial Ca 21 current that was activated by Ca 21 
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effect on this I MCU ( Supplementary Fig. 8a) , indicating that the beneficial actions of CaMKII inhibition on mPTP were distinct from the effects of CaMKII on the MCU. I MCU was increased by addition of a constitutively active, monomeric CaMKII mutant (T287D) 23 to the pipette solution (equivalent to the mitochondrial matrix) in the presence of ATP ( Fig. 2b and Supplementary Fig. 8b ). Addition of the T287D mutant CaMKII did not increase I MCU in the presence of a non-hydrolysable ATP analogue, adenosine 59-(b,c-imido) triphosphate tetralithium salt (Fig. 2b) , or in the absence of ATP (data not shown). Furthermore, a catalytically incompetent CaMKII mutant (K43M) 24 failed to increase I MCU in the presence of activating ATP and calmodulin ( Fig. 2b and Supplementary Fig. 8b ). Therefore the catalytic activity of CaMKII was necessary to increase I MCU . As a control, inhibiting serine/threonine phosphatases with calyculin A increased I MCU ( Fig. 2c and Supplementary Fig. 8c 21 as the charge carrier ( Fig. 2d and Supplementary Fig. 8d ). In contrast, when Na 1 was substituted for Ca 21 , a condition that does not support CaMKII activation, differences were not apparent between wild-type and CaMKIINexpressing mitoplasts, indicating that CaMKIIN was unlikely to affect MCU expression ( Supplementary Fig. 8d ). Ru360 nearly and equivalently eliminated I MCU in all genotypes, suggesting that MCU antagonist sensitivity was not affected by CaMKIIN ( Fig. 2d and Supplementary  Fig. 8a ). CaMKII and MCU co-immunoprecipitated from myocardial mitochondria lysate ( Fig. 2e ), suggesting that CaMKII is associated with MCU in the heart. CaMKII enhances Ca 21 currents through sarcolemmal voltage-gated Ca 21 channels (Ca V 1.2) 25 and intracellular Ca 21 -gated ryanodine receptor Ca 21 release channels 26 by phosphorylation of defined serines/threonines 25, 26 . We identified two putative CaMKII target sites on MCU, serines 57 and 92, and mutated them both to alanines, to test for a direct effect of CaMKII on MCU. We over expressed wild-type and S57A/S92A MCU in HEK cells and measured I MCU from isolated mitoplasts. Constitutively active, monomeric CaMKII (T287D) added to the pipette solution failed to increase I MCU in mitochondria from cells transfected with S57A/S92A MCU compared to wild-type MCU transfections ( Fig. 2f and Supplementary Fig. 8e ). In contrast, CaMKII added to the bath solution failed to affect I MCU recorded from wild-type or S57A/S92A overexpressing mitoplasts (not shown). These studies, using a CaMKII-resistant S57A/S92A MCU mutant, suggest that the amino terminus of MCU is facing the Replacing ATP with a nonhydrolysable analogue (non-hATP) does not allow a CaMKII-dependent increase in I MCU. Samples tested were: control (CaM 1 ATP, n 5 5); T287D (T287D 1 ATP, n 5 7); K43M (K43M 1 CaM 1 ATP, n 5 3); and non-hATP T287D (T287D 1 non-hATP, n 5 3), (ATP or non-hATP at 0.1 mM, CaM at 50 mM, all mutant CaMKII at 0.5 mM, *P , 0.01, **P , 0.001, ***P , 0.0001 at 20 min.). c, I MCU recorded using mitoplasts of wild-type hearts after addition of 0.2 mM Ca 21 (control, n 5 7), 0.2 mM Ca 21 with 100 nM calyculin A (CA, n 5 9) and 0.2 mM Ca 21 with 100 nM calyculin A plus 0.5 mM CaMKII T287D (CA T287D, n 5 7) (***P , 0.0001). d, I MCU recorded from wild-type, CaMKIIN and mtCaMKIIN mitochondria. Na 1 current (150 mM) recorded in the absence of Ca 21 bath (intermembrane space equivalent) or with Ru360 (10 nM). For Ca 21 : (WT, n 5 10; CaMKIIN, n 5 10; mtCaMKIIN, n 5 7), for Na 1 : (WT, n 5 15; CaMKIIN, n 5 13; mtCaMKIIN, n 5 12); and for Ru360: (WT, n 5 8; CaMKIIN, n 5 8; mtCaMKIIN, n 5 5). (**P , 0.001, ***P , 0.0001). NS, not significant. e, MCU and CaMKII coimmunoprecipitate from heart mitochondrial lysate. f, I MCU recorded from HEK cell mitoplasts without transfection (no transfection) or transfection of wild-type MCU (WT) or S57A/S92A MCU mutant (S57A/S92A). For control samples (Ctrl), without addition of CAMKII T287D: (no transfection, n 5 7; WT MCU, n 5 7; S57A/S92A MCU mutant, n 5 7); for T287D: (WT MCU, n 5 8; S57A/S92A MCU mutant, n 5 9); and for RU360: (WT MCU, n 5 6; S57A/S92A MCU mutant, n 5 6). HEK mitoplast Ca 1 currents were inhibited by Ru360 (10 nM). (All data represent means 6 s.e.m., except for inset, see a. P value comparisons as indicated using Bonferroni post (ANOVA) test.) LETTER RESEARCH mitochondrial matrix 4 . Altogether, these data show that CaMKII interacts with MCU and promotes mitochondrial Ca 21 entry, probably by catalysing phosphorylation of serines 57 and 92, consistent with the concept that MCU is an important CaMKII target in mitochondria.
We next used the mtCaMKIIN mice to determine if mitochondrial CaMKII inhibition was sufficient to explain the protective effects of CaMKII inhibition on ischaemic injury in isolated perfused hearts in the absence of glucose ( Supplementary Fig. 2) 7, 11 . We found that after ischaemia reperfusion injury, hearts from mtCaMKIIN mice had preserved mechanical function (Fig. 3a) , reduced myocardial infarction size (Fig. 3b, c) , preserved mitochondrial integrity (Fig. 3d, e ) and reduced Caspase 9 activity (Fig. 3f ) compared to wild-type littermate control hearts. Baseline left ventricular developed pressures were similar between wild-type and mtCaMKIIN hearts ( Supplementary  Fig. 9 ). We found no difference in left ventricular mechanical recovery (P 5 0.976) between wild-type and mtCaMKIIN hearts treated with CsA, and CsA added no further protection for mtCaMKIIN hearts subjected to ischaemia reperfusion injury (P 5 0.946). Neurohumoral toxicity is a major cause of adverse outcomes after myocardial infarction, including heart failure 27 , and b-adrenergic receptor antagonist drugs are a current favoured therapeutic treatment for reducing myocardial death and dysfunction after ischaemic injury and myocardial infarction 27 . CaMKII is activated by isoprenaline in heart and CaMKII inhibition protects against isoprenaline-mediated myocardial injury 7, 8 .
The protective effects of mtCaMKIIN expression were also evident in vivo, because mtCaMKIIN mice showed fewer TdT-mediated dUTP nick end labelling (TUNEL)-stained nuclei, a measurement of cell death, than wild-type controls 5 h after a myocardial infarction (Fig. 4a, b ) or 30 min after isoprenaline treatment (Fig. 4b) . Thus, mitochondrial targets seem to be essential for the cardioprotective benefits of CaMKII inhibition in a diverse set of clinically-relevant injury models.
Our findings identify CaMKII as a modulator of mitochondrial Ca 21 homeostasis and a crucial component of a final Ca 21 -dependent pathway in heart disease due to ischaemia and neurohumoral toxicity, by showing that CaMKII increases I MCU and that CaMKII inhibition reduces I MCU and the mPTP opening. Our study suggests that CaMKII inhibition could reduce adverse responses, including death, to common forms of pathological myocardial stress by multivalent actions on mitochondria, including I MCU inhibition and blunting Ca 21 responsiveness of mPTP.
METHODS SUMMARY
CaMKII inhibition was achieved by expressing CaMKIIN, an endogenous brainderived inhibitor protein 13 . In vivo experiments were done with transgenic mice expressing the inhibitor under a-MHC control to limit expression to the heart 11 , in addition to cellular localization specified by a palmitoyl amino acid sequence addition to CaMKIIN (CaMKIIN mice) or a Cox8a (mitochondrial localization sequence added to CaMKIIN (mtCaMKIIN mice)). Opening of mPTP was measured by both a mitochondria swelling assay and the fluorescent dye indicator, JC-1. Extra-mitochondrial calcium in permeabilized isolated cardiomyocytes 28 was measured using Calcium green-5N. Mitochondrial Ca 21 uptake was measured in HeLa cells transfected with plasmids expressing the mitochondrial-targeted Cameleon (4mtD3CPV) along with mitochondrial-targeted CaMKIIN or a control plasmid. I MCU was measured in mitoplast preparations 3 from cardiomyocytes of wild-type or transgenic mouse hearts or HEK cells expressing wild-type or mutated MCU. Ex vivo hearts were prepared to measure left ventricular developed pressure 29 with 2 mM pyruvate as the energy source. a, LVDP recovery after ischaemia reperfusion as a percentage of the baseline value (*P 5 0.026). b, Representative 2,3,5-triphenyltetrazolium chloride (TTC) stained heart sections from a. The dark red staining represents living myocardium and the solid black outlines form boundaries demarcating viable from dead tissue. c, Relative area of infarct in TTC-stained hearts normalized to wild type, measured as in Supplementary Fig. 2e ; *P 5 0.006. d, Representative TEM images from hearts undergoing ischaemia reperfusion injury treatment as in a. e, Mitochondrial injury scores for TEM studies by the criteria used in Supplementary Fig. 2h . A higher score indicates an increased response to injury (*P 5 0.003, more than 500 mitochondria from at least 10 random fields were counted per genotype). f, Caspase 9 activity from hearts treated as in panel a (*P 5 0.033, n 5 number of hearts per genotype). Data represent means 6 s.e.m. 
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METHODS
Transgenic mice. Animals were maintained in the University of Iowa Animal Facility and treated in accordance with Institutional Animal Care and Use Committee guidelines (PHS Animal Welfare Assurance, A3021-01). CaMKIIN transgenic mice (C57BL/6 background) were generated as described 13 for a control. Hearts were perfused for 10 min to ensure metabolic equilibrium, followed by 20 or 30 min of global ischaemia and then 50 min of reperfusion. Measurements were recorded from each heart for the entire duration of perfusion.
Heart infarct size and caspase 9 activity assay. Following the ischaemia reperfusion protocol shown in Supplementary Fig. 2 , hearts were immediately frozen. Three 0.5-mm sections were cut from frozen hearts, labelled with 5% (wt/vol) 2,3,5-triphenyltetrazolium chloride (TTC) in PBS buffer and fixed in 10% formalin. Caspase 9 activity assays were performed on tissue lysate following manufacturer's protocol (Invitrogen) and normalized to protein concentration (mg ml 21 ). Transmission electron microscopy. Hearts were fixed in 2.5% gluteraldehyde and 0.1 M Na cacodylate buffer overnight at 4uC, followed by three 20-min washes in 0.1 M pH 7.2 sodium cacodylate buffer, fixed in 4 % OsO 4 , washed in 0.1 M sodium cacodylate buffer, then dH 2 O, followed by 2.5% uranyl acetate. A series of ethanol washes was used to dehydrate the sample, which was then exchanged with an ethanol and Spurr's mixture series of increasing Spurr's concentration, culminating in a final solution of 100% Spurr's resin. Hearts were embedded in Spurr's resin at 60 uC for 24-48 h. Ultramicrotomy was carried out at 90 nm and samples collected on 200 mesh for formvard grids for staining with uranyl and lead. Stained sections were examined with a JEOL JEM-1230 transmission electron microscope and digital images were collected with a Gatan UltraScan 1000 2k 3 2k CCD camera. Mitochondrial isolation and subcellular fractionation. Isolation of mitochondria was performed on ice. Freshly collected mouse hearts were injected with 1.0% protease XXIV in MSE buffer (5 mM MOPS, 70 mM sucrose, 2 mM EGTA, 220 mM mannitol, pH 7.2 with KOH) then homogenized. HEK cells were washed then homogenized. Nuclei and unbroken cells were pelleted by centrifugation twice at 600g for 10 min. The crude mitochondrial and cytosolic fraction was obtained from the supernatant by centrifugation at 8,500g for 20 min. The pellet was further purified with a 40% percoll gradient, washed twice in MSE buffer then resuspended in 200 ml MSE with protease inhibitors. For mitoplast preparation, mitochondria were resuspended in hypotonic solution (5 mM sucrose, 5 mM HEPES and 1 EGTA (pH 7.2 with KOH) for 5 min to remove outer membrane. After sedimenting for 5 min at 4,000g, mitoplasts were resuspended in 750 mM KCl, 100 mM HEPES and 1 mM EGTA (pH 7.2 with KOH). MCU current recording (whole-mitoplast configuration). Signals were measured with an Axon 200B patch-clamp amplifier controlled by a personal computer
